SYK · Investment summary · as of 29 July 2026
Priced slightly ahead of what the business has demonstrated
Business type: Compounder
The operating path required by today's price is not achievable on the evidence.
At $346.57, SYK requires a 15% five-year revenue growth rate to justify its enterprise value — more than the business has ever demonstrated, at 11%.
The value rests on an exit multiple of 22.7x and a terminal operating margin of 20%. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: The Q1-2026 10-Q already warns that manual workarounds "may increase the risk of errors, delays or data integrity issues (including with respect to… processes supporting financial and ope
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | Not determined — the operating driver is not stated in one place |
| What do we forecast? | Revenue growth of 11% demonstrated; a terminal operating margin of 20%; an exit multiple of 22.7x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On revenue growth, the difference between what the price requires and what the business has demonstrated is -4.3 percentage points. |
| What is it worth? | Twelve-month target $390.00, +13% from the struck price. Scenario-weighted expected return net of costs +12.5%. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
Not determined — no falsifiable operating conditions are on file for this name, so the thesis cannot be reduced to a small number of testable claims
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| 29 October 2026 | Next results (date estimated, not issuer-confirmed) | Revenue and margin in line with, or above, the house path | A miss that moves the full-year path below the guided floor |
Dates marked as estimated are drawn from the company’s own reporting cadence, not from an announcement.
The Q1-2026 10-Q already warns that manual workarounds "may increase the risk of errors, delays or data integrity issues (including with respect to… processes supporting financial and ope
Not determined — no falsifiable invalidation conditions are on file, so this position cannot be risk-monitored
On approach to the $390.00 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Not determined | Is the business worth owning under its declared economic type? Not established on the evidence on file. |
| Valuation | Not met | Is the operating path required by today's price achievable? |
| Liquidity | Not determined | Can the intended position be built and exited in the right vehicle? Not established on the evidence on file. |
| Downside | Met | The Q1-2026 10-Q already warns that manual workarounds "may increase the risk of errors, delays or data integrity issues (including with respect to… processes supporting financial and ope |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Not determined | Is there a dated event that resolves the disagreement? Not established on the evidence on file. |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The gap between what today's price requires and what the business has demonstrated is -4.3 percentage points, and that gap — not the multiple — is the case that the security is mispriced. The most important unresolved uncertainty is whether this is a business worth owning at all — the evidence for its quality is not established. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $304.98, which forces an immediate review.